Employees: 1,523
Size Frontage (1521.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $542M, the 727th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$2.08 on 18 Nov 2026.
Performance Over six months the shares gained 112.8%, against -19.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — highest of 19 in its peer set.
Growth Revenue grew 10.3% over the last twelve months (peer median +3.9%); the operating margin is 7.9% (peer median -108.5%).
Valuation It trades at 24.6× forward earnings against a peer median of 29.9× (4th cheapest of 7).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.7 points below its cost of capital (7.6% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$2.17B | HK$2.00B | HK$1.99B | HK$2.03B | HK$1.96B |
| Revenue growth | — | +1% | -2% | +4% | — |
| Gross profit | HK$561M | HK$539M | HK$545M | HK$614M | HK$698M |
| EBITDA | HK$452M | HK$397M | HK$356M | HK$432M | HK$493M |
| Net income | HK$83.0M | HK$53.0M | HK$6.17M | HK$84.6M | HK$202M |
| Free cash flow | HK$255M | HK$219M | HK$73.4M | HK$130M | HK$113M |
| Capital expenditure | HK$111M | HK$90.9M | HK$202M | HK$166M | HK$376M |
| Total debt | n/a | HK$993M | HK$1.20B | HK$1.13B | HK$922M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1521.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +93.1% | -15.3% | highest of 21 |
| 6-month return | +112.8% | -19.4% | highest of 19 |
| Distance from 52-week high | -6.1% | -49.8% | highest of 21 |
| Revenue growth (TTM) | +10.3% | +3.9% | 7th highest of 16 |
| Operating margin | 7.9% | -108.5% | 2nd highest of 17 |
| Forward P/E | 24.6× | 29.9× | 4th cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | 14.3% | 31.9% | least demanding of 4 |
| Growth delivered (Del g) | +15.4% | +27.2% | 2nd lowest of 4 |
| Hurdle (Req g minus delivered) | -1.1 pp | +4.7 pp | 2nd least demanding of 4 |
| ROIC minus cost of capital | -3.7 pp | -3.9 pp | 6th highest of 12 |
| EV / EBITDA | 11.2× | n/a | — |
| Net debt / EBITDA | 1.8× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Frontage 1521.HK | Hong Kong | $542M | +113% | +10% | 8% | 24.6× | 14.3% | +15.4% |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | n/a | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 11.7× | n/a | n/a |
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 69.3× | 31.9% | +27.2% |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | n/a | n/a | n/a |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 431.5× | 39.8% | +143.5% |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | n/a | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | n/a | n/a | n/a |
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | n/a | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 21.5× | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | n/a | 29.4% | +7.0% |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | n/a | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 37.5× | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | n/a | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 22.3× | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | n/a | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | n/a | n/a | n/a |